Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study
Authors:
- Leopoldo Pérez de IslaLILeopoldo Pérez de Isla
- Jose L. Díaz-DíazJDJose L. Díaz-Díaz
- Manuel J. RomeroMRManuel J. Romero
- Ovidio Muñiz-GrijalvoOMOvidio Muñiz-Grijalvo
- Juan D. MediavillaJMJuan D. Mediavilla
- Rosa ArgüesoRARosa Argüeso
- Raimundo de AndrésRARaimundo de Andrés
- Francisco FuentesFFFrancisco Fuentes
- Juan F. Sánchez Muñoz-TorreroJMJuan F. Sánchez Muñoz-Torrero
- Patricia RubioPRPatricia Rubio
- 1 January 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (1) , e016206
Abstract
BACKGROUND: Intensive lipid-lowering therapy may induce coronary atherosclerosis regression. Nevertheless, the factors underlying the effect of lipid-lowering therapy on disease regression remain poorly characterized. Our aim was to determine which characteristics of atherosclerotic plaque are associated with a greater reduction in coronary plaque burden (PB) after treatment with alirocumab in patients with familial hypercholesterolemia. METHODS: The ARCHITECT study (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architecture and Composition) is a phase IV, open-label, multicenter, single-arm clinical trial to assess the effect of the treatment with alirocumab for 78 weeks on the coronary atherosclerotic PB and its characteristics in subjects with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. Participants underwent a coronary computed tomographic angiography at baseline and a final one at 78 weeks. Every patient received alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy. RESULTS: One hundred and four patients were enrolled. Median age was 53.3 (46.2–59.4) years and 54 were women (51.9%). The global coronary PB changed from 34.6% (32.5%–36.8%) at entry to 30.4% (27.4%–33.4%) at follow-up, which is −4.6% (−7.7% to −1.9%; P P P =0.002) and a higher proportion of unstable core (β, 0.15 [0.08–0.22]; P <0.001) were significantly related to PB regression. CONCLUSIONS: Treatment with alirocumab in addition to high-intensity statin therapy might produce a greater PB regression in patients with familial hypercholesterolemia with higher baseline PB and in those with larger unstable core. Further studies are needed to corroborate the hypothesis raised by these results. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05465278.Keywords
This publication has 20 references indexed in Scilit:
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial InfarctionJAMA, 2022
- Coronary Atherosclerotic Plaque RegressionJACC, 2022
- Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque CompositionJAMA Cardiology, 2021
- Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography studyAtherosclerosis, 2021
- Coronary atheroma regression and adverse cardiac events: A systematic review and meta-regression analysisAtherosclerosis, 2019
- Enhanced characterization of calcified areas in intravascular ultrasound virtual histology images by quantification of the acoustic shadow: validation against computed tomography coronary angiographyThe International Journal of Cardiovascular Imaging, 2015
- Effect of statin treatment on coronary plaque progression – A serial coronary CT angiography studyAtherosclerosis, 2013
- Automatic quantification and characterization of coronary atherosclerosis with computed tomography coronary angiography: cross-correlation with intravascular ultrasound virtual histologyThe International Journal of Cardiovascular Imaging, 2013
- Reproducibility of computed tomography angiography data analysis using semiautomated plaque quantification software: implications for the design of longitudinal studiesThe International Journal of Cardiovascular Imaging, 2012
- Intravascular Ultrasound-Derived Measures of Coronary Atherosclerotic Plaque Burden and Clinical OutcomeJACC, 2010